文献速递重症综合管理与镇静镇痛心脑血管急症

对意识障碍并携带侵入性装置(含脑室外引流)的重症患者实施程序化电动直立训练的安全性

Safety of Protocolized Motorized Verticalization in Critically Ill Patients With Impaired Consciousness and Invasive Devices, Including External Ventricular Drains.
PubMed 文献 · Crit Care Explor · 2026-09-25
一句话结论单中心回顾性队列显示,对GCS 8±3、90.9%插管、36.4%同时携带ETT+CVC+EVD的重症患者行程序化电动直立训练,未发生装置脱出。

队列高急重症度(平均GCS 8±3),90.9%插管、93.9%有CVC、36.4%同时携带ETT、CVC和EVD。主要终点装置脱出为零,无因ICP危象或血流动力学不稳定终止治疗;用rule-of-three法估计总体不良事件风险上界<0.7%。结论支持进一步多中心评估。

要点

  • rule-of-three分析:以角度暴露为事件机会分母,总体不良事件风险上界<0.7%,中等角度<1.1%,EVD相关暴露<2%。
  • 大多数暴露(65.2%)在中等角度(30°–45°)完成,累计14,443分钟;部分EVD患者耐受>45°,最高达75°。
  • 方案为VitalGo Total Lift Bed从10°起始、按生理耐受递增角度,每日3–4次,时长与角度递增个体化。
  • 36.4%患者同时携带ETT、CVC和EVD;该人群装置脱出为零,但研究为单中心回顾性,需多中心验证。

适用人群与场景

  • 成人重症患者,在Level 1创伤与综合卒中中心的神经重症监护单元接受治疗。
  • 纳入标准:2024年10月1日至2025年10月1日期间按机构方案接受电动直立训练治疗者。
  • 队列特征:平均GCS 8±3;90.9%插管;93.9%有中心静脉导管;36.4%同时携带气管插管、中心静脉导管和脑室外引流。

诊断标准与关键阈值

  • 原文未提及诊断标准或启动/停止的量化阈值。
  • 角度强度分类:低角度<30°,中等角度30°–45°,高角度>45°。
  • 方案从10°起始,按生理耐受递增角度;每次治疗时长和角度递增个体化。

处置流程与药物剂量

  • 第一步:使用VitalGo Total Lift Bed进行程序化电动直立训练,采用分级直立承重方式。
  • 第二步:从10°开始,根据生理耐受逐步递增角度。
  • 第三步:每日3–4次治疗,每次时长和角度递增个体化。
  • 第四步:角度强度按低(<30°)、中等(30°–45°)、高(>45°)分类记录。

红旗征与不能漏的情况

  • 原文未提及因ICP危象或血流动力学不稳定而终止治疗的案例;研究期间无此类终止。
  • 原文未提及其他红旗征或需立刻处理的情况。

研究设计与关键结果

  • 人群:神经重症监护单元成人患者,平均GCS 8±3;90.9%插管,93.9%有CVC,36.4%同时有ETT、CVC和EVD。
  • 干预:程序化电动直立训练(VitalGo Total Lift Bed),从10°起始按生理耐受递增,每日3–4次。
  • 主要终点:装置脱出——所有治疗和暴露中均无装置脱出发生。
  • 关键次要终点:无因ICP危象或血流动力学不稳定终止治疗;65.2%的暴露在中等角度完成,累计14,443分钟;部分EVD患者耐受>45°,最高达75°。
  • rule-of-three分析:以角度暴露为事件机会分母,总体不良事件风险上界<0.7%,中等角度<1.1%,EVD相关暴露<2%。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。

对床旁实践的改变

  • 对意识障碍并携带ETT、CVC或EVD的神经重症患者,程序化电动直立训练在本单中心队列中未发生装置脱出,可支持在类似人群中谨慎开展并进一步评估。
  • 方案从10°起始、按生理耐受递增、每日3–4次,可作为实施参考;但研究为回顾性、单中心、样本小,不能据此形成通用推荐。
  • 部分EVD患者耐受>45°(最高75°),但EVD相关暴露的不良事件风险上界<2%,需个体化评估。
  • 原文未提及该方案的适用与不适用人群的明确界定,常见陷阱未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Critically ill patients with impaired consciousness and concurrent invasive devices remain understudied in ICU mobilization research. Motorized verticalization enables graded upright weight bearing without requiring active patient participation, but device safety in high-acuity neurocritical care populations is not well characterized. We evaluated the safety of a protocolized motorized verticalization program with invasive device dislodgement as the primary outcome.

DESIGN: Single-center retrospective cohort study.

SETTING: Neurocritical care unit at a Level 1 trauma and comprehensive stroke center.

PATIENTS: Adults receiving motorized verticalization therapy between October 1, 2024, and October 1, 2025, according to the institutional protocol.

INTERVENTIONS: Protocolized motorized verticalization therapy using a graded upright weight-bearing approach with the VitalGo Total Lift Bed, beginning at 10° and progressing incrementally based on physiologic tolerance. Sessions occurred three to four times daily with individualized duration and angle advancement. Angle intensity was categorized as low (< 30°), moderate (30°-45°), or high (> 45°).

MEASUREMENTS AND MAIN RESULTS: Thirty-three patients underwent 153 treatment sessions comprising 409 verticalization angle exposures. The cohort was high acuity (mean Glasgow Coma Scale 8 ± 3); 90.9% were intubated, 93.9% had central venous catheters (CVCs), and 36.4% had concurrent endotracheal tubes (ETTs), CVCs, and external ventricular drains (EVDs) . No device dislodgements occurred across any session or exposure, and no session termination due to ICP crisis or hemodynamic instability. Applying the rule-of-three statistical analysis, using angle exposures as the event opportunity denominator, the upper bound adverse event risk was less than 0.7% overall, less than 1.1% for moderate angles, and less than 2% for EVD-associated exposure. Most exposures (65.2%) occurred at moderate angles, totaling 14,443 minutes. A subset of EVD patients tolerated angles greater than 45°, including up to 75°.

CONCLUSIONS: Protocolized motorized verticalization therapy was implemented without observed ETT, CVC, or EVD dislodgement in this high-acuity cohort. Findings support further multicenter evaluation of motorized verticalization effects on device safety, physiologic tolerance, neurologic recovery, and patient-centered outcomes.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Dakakni T, Roebuck LD. Safety of Protocolized Motorized Verticalization in Critically Ill Patients With Impaired Consciousness and Invasive Devices, Including External Ventricular Drains. Crit Care Explor. 2026. PMID: 42804361. doi:10.1097/CCE.0000000000001491

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。